Recently, linagliptin is added to incretin-based therapies for the treatment of Type 2 diabetes mellitus (T2DM). Unlike other dipeptidyl peptidases 4 inhibitors, linagliptin is excreted mainly through the enterohepatic system and can be used without dose adjustment in patients with renal impairment. The American Diabetes Association and European Association for the Study of Diabetes guidelines suggested the use of linagliptin as first-line agents in people who did not tolerate metformin for the management of T2DM.
As compared to other incretin-based therapies, linagliptin enhances insulin secretion, decreases glucagon production, slows gastric emptying, promotes satiety, and reduces appetite. Further, linagliptin has several advantages such as a lack of severe hypoglycemia, weight neutrality, and good overall tolerability. 1 In this regard, Boehringer Ingelheim India and Docplexus…
